KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets (2018 - 2025)

Castle Biosciences' Assets history spans 7 years, with the latest figure at $578.6 million for Q4 2025.

  • For Q4 2025, Assets rose 8.91% year-over-year to $578.6 million; the TTM value through Dec 2025 reached $578.6 million, up 8.91%, while the annual FY2025 figure was $578.6 million, 8.91% up from the prior year.
  • Assets for Q4 2025 was $578.6 million at Castle Biosciences, up from $562.8 million in the prior quarter.
  • Across five years, Assets topped out at $578.6 million in Q4 2025 and bottomed at $425.4 million in Q2 2023.
  • The 5-year median for Assets is $458.1 million (2022), against an average of $474.9 million.
  • The largest annual shift saw Assets surged 263.66% in 2021 before it decreased 7.19% in 2023.
  • A 5-year view of Assets shows it stood at $462.6 million in 2021, then fell by 3.3% to $447.3 million in 2022, then increased by 1.34% to $453.3 million in 2023, then grew by 17.18% to $531.2 million in 2024, then grew by 8.91% to $578.6 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Assets are $578.6 million (Q4 2025), $562.8 million (Q3 2025), and $544.7 million (Q2 2025).